Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

被引:23
|
作者
Timmins, Hannah C. [1 ]
Mizrahi, David [2 ]
Li, Tiffany [1 ]
Kiernan, Matthew C. [1 ,3 ,4 ]
Goldstein, David [2 ,5 ]
Park, Susanna B. [1 ]
机构
[1] Univ Sydney, Fac Med & Hlth, Brain & Mind Ctr, Sydney, NSW, Australia
[2] UNSW Sydney, Fac Med, Prince Wales Clin Sch, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Royal Prince Alfred Hosp, Camperdown, NSW, Australia
[5] Prince Wales Hosp, Dept Med Oncol, Randwick, NSW, Australia
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
Chemotherapy; Neuropathy; Risk factors; Obesity; Diabetes; Physical activity; QUALITY-OF-LIFE; CANCER-PATIENTS; COLORECTAL-CANCER; PHYSICAL-ACTIVITY; BREAST-CANCER; SENSORY NEUROPATHY; BODY-MASS; EXERCISE; SURVIVORS; WOMEN;
D O I
10.1007/s11764-021-00988-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common dose-limiting toxicity of cancer treatment causing functional impairment and impacting quality of life. Effective prevention and treatment of CIPN are lacking, and CIPN risk factors remain ill-defined. Metabolic syndrome and associated conditions have emerged as potential risk factors, due to their high prevalence and independent association with nerve dysfunction. This systematic review aimed to investigate the association between these common metabolic-lifestyle factors and CIPN. Methods Searches were undertaken using Medline, Embase, CINAHL, Scopus, and Web of Science databases, with additional studies identified from bibliographic references cited by original and review articles. Articles that analyzed metabolic-lifestyle risk factors associated with CIPN for patients treated with platinum- or taxane-based chemotherapy were included. Results Searches identified 6897 titles; 44 articles had full text review, with 26 studies included. Overall incidence of neuropathy ranged from 16.9 to 89.4%. Obesity had the most consistent patient-oriented evidence as a risk factor for CIPN, with moderate evidence suggesting diabetes did not increase CIPN incidence or severity. A limited number of studies supported an association with low physical activity and greater CIPN risk. Conclusions Comorbidities and lifestyle factors, particularly obesity and low physical activity, may contribute to the development of CIPN. The implementation of sensitive outcome measures in large-scale clinical trials is required to further elucidate CIPN risk factors and evaluate if changes in lifestyle would improve long-term CIPN outcomes for cancer survivors. Implications for Cancer Survivors Better understanding of CIPN risk profiles may inform personalized medicine strategies and help elucidate pathophysiological mechanisms which could be targeted for neuroprotection.
引用
收藏
页码:222 / 236
页数:15
相关论文
共 50 条
  • [1] Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review
    Hannah C. Timmins
    David Mizrahi
    Tiffany Li
    Matthew C. Kiernan
    David Goldstein
    Susanna B. Park
    Journal of Cancer Survivorship, 2023, 17 : 222 - 236
  • [2] Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy
    Molassiotis, Alex
    Cheng, Hui Lin
    Leung, Kwun To
    Li, Yu Chung
    Wong, Kam Hung
    Au, Joseph Siu Kie
    Sundar, Raghav
    Chan, Alexandre
    De Ng, Terrence Rong
    Suen, Lorna K. P.
    Chan, Choi Wan
    Yorke, Janette
    Lopez, Violeta
    BRAIN AND BEHAVIOR, 2019, 9 (06):
  • [3] The Relationship of Chemotherapy-Induced Peripheral Neuropathy and Obesity: A Systematic Review
    Jesse, Mary
    REHABILITATION ONCOLOGY, 2019, 37 (04) : 167 - 175
  • [4] Chemotherapy-induced peripheral neuropathy and rehabilitation: A review
    Zhang, Shangming
    SEMINARS IN ONCOLOGY, 2021, 48 (03) : 193 - 207
  • [5] Lifestyle-Related Factors in the Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A Systematic Review
    Derksen, Tess M. E.
    Bours, Martijn J. L.
    Mols, Floortje
    Weijenberg, Matty P.
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, 2017
  • [6] Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives
    Ewertz, Marianne
    Qvortrup, Camilla
    Eckhoff, Lise
    ACTA ONCOLOGICA, 2015, 54 (05) : 587 - 591
  • [7] Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy
    Cox-Martin, Emily
    Trahan, Lisa H.
    Cox, Matthew G.
    Dougherty, Patrick M.
    Lai, Emily A.
    Novy, Diane M.
    SUPPORTIVE CARE IN CANCER, 2017, 25 (06) : 1873 - 1879
  • [8] Beneficial effects of exercise on chemotherapy-induced peripheral neuropathy and sleep disturbance: A review of literature and proposed mechanisms
    Whalen, L. Brett
    Wright, W. Zachary
    Kundur, Priyanka
    Angadi, Siddhartha
    Modesitt, Susan C.
    GYNECOLOGIC ONCOLOGY REPORTS, 2022, 39
  • [9] Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy
    Kleckner, Ian R.
    Jusko, Todd A.
    Culakova, Eva
    Chung, Kaitlin
    Kleckner, Amber S.
    Asare, Matthew
    Inglis, Julia E.
    Loh, Kah Poh
    Peppone, Luke J.
    Miller, Jessica
    Melnik, Marianne
    Kasbari, Samer
    Ossip, Deborah
    Mustian, Karen M.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) : 521 - 532
  • [10] Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties
    Griffith, Kathleen A.
    Merkies, Ingemar S. J.
    Hill, Elizabeth E.
    Cornblath, David R.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2010, 15 (04) : 314 - 325